DEVELOPMENT AND VALIDATION OF UV SPECTROPHOTOMETRIC AND REVERSED PHASE‑HIGH PERFORMANCE LIQUID CHROMATOGRAPHY ‑ PDA METHODS FOR THE ESTIMATION OF ALOGLIPTIN BENZOATE

Objective: To develop and validate simple, rapid, precise, accurate, and economical UV spectrophotometric and reverse phase high performanceliquid chromatographic methods for the estimation of alogliptin benzoate (AGP).Methods: UV spectrophotometric method was performed using UV/Vis double beam spectrophotometer with a spectral bandwidth of 1 nm and1.0 cm matched quartz cells. The maximum absorbance of AGP was observed at 276 nm using methanol as solvent. Reversed phase-high performanceliquid chromatography (RP-HPLC) method was carried out on a Unisol reverse phase C18 column (150 mm × 4.6 mm, 3 μm) with a mobile phasecomposed of methanol and 10 mM ammonium acetate buffer (adjusted to pH 5.0 with glacial acetic acid) in the ratio of 80:20 v/v with a flow rate of0.8 ml/minutes.Results: The linearity of methods was found to be in the range of 5-35 µg/ml (UV) and 20-100 µg/ml (RP-HPLC) and the correlation coefficient was0.999 for both the methods. The regression equations were y = 0.028x + 0.023 (UV) and y = 28,58,942x - 4,33,647 (HPLC). The retention time of AGPwas 2.37 minutes.Conclusion: The proposed methods were validated in terms of linearity, precision, accuracy, specificity, robustness, limit of detection, and limit ofquantitation as per International Conference on Harmonization Q2 R1 guidelines. Thus, the proposed methods are novel, sensitive, and reliable andcan be successfully used for the quantitation of AGP.Keywords: Alogliptin benzoate, UV-visible spectrophotometer, Reversed phase-high performance liquid chromatography, International Conferenceon Harmonization guidelines

Measuring routine childhood vaccination coverage in 204 countries and territories, 1980-2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1

Background: Measuring routine childhood vaccination is crucial to inform global vaccine policies and programme implementation, and to track progress towards targets set by the Global Vaccine Action Plan (GVAP) and Immunization Agenda 2030. Robust estimates of routine vaccine coverage are needed to identify past successes and persistent vulnerabilities. Drawing from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2020, Release 1, we did a systematic analysis of global, regional, and national vaccine coverage trends using a statistical framework, by vaccine and over time. // Methods: For this analysis we collated 55 326 country-specific, cohort-specific, year-specific, vaccine-specific, and dose-specific observations of routine childhood vaccination coverage between 1980 and 2019. Using spatiotemporal Gaussian process regression, we produced location-specific and year-specific estimates of 11 routine childhood vaccine coverage indicators for 204 countries and territories from 1980 to 2019, adjusting for biases in country-reported data and reflecting reported stockouts and supply disruptions. We analysed global and regional trends in coverage and numbers of zero-dose children (defined as those who never received a diphtheria-tetanus-pertussis [DTP] vaccine dose), progress towards GVAP targets, and the relationship between vaccine coverage and sociodemographic development. // Findings: By 2019, global coverage of third-dose DTP (DTP3; 81·6% [95% uncertainty interval 80·4–82·7]) more than doubled from levels estimated in 1980 (39·9% [37·5–42·1]), as did global coverage of the first-dose measles-containing vaccine (MCV1; from 38·5% [35·4–41·3] in 1980 to 83·6% [82·3–84·8] in 2019). Third-dose polio vaccine (Pol3) coverage also increased, from 42·6% (41·4–44·1) in 1980 to 79·8% (78·4–81·1) in 2019, and global coverage of newer vaccines increased rapidly between 2000 and 2019. The global number of zero-dose children fell by nearly 75% between 1980 and 2019, from 56·8 million (52·6–60·9) to 14·5 million (13·4–15·9). However, over the past decade, global vaccine coverage broadly plateaued; 94 countries and territories recorded decreasing DTP3 coverage since 2010. Only 11 countries and territories were estimated to have reached the national GVAP target of at least 90% coverage for all assessed vaccines in 2019. // Interpretation: After achieving large gains in childhood vaccine coverage worldwide, in much of the world this progress was stalled or reversed from 2010 to 2019. These findings underscore the importance of revisiting routine immunisation strategies and programmatic approaches, recentring service delivery around equity and underserved populations. Strengthening vaccine data and monitoring systems is crucial to these pursuits, now and through to 2030, to ensure that all children have access to, and can benefit from, lifesaving vaccines

Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990-2021: findings from the Global Burden of Disease Study 2021

Background Anaemia is a major health problem worldwide. Global estimates of anaemia burden are crucial for developing appropriate interventions to meet current international targets for disease mitigation. We describe the prevalence, years lived with disability, and trends of anaemia and its underlying causes in 204 countries and territories. Methods We estimated population-level distributions of haemoglobin concentration by age and sex for each location from 1990 to 2021. We then calculated anaemia burden by severity and associated years lived with disability (YLDs). With data on prevalence of the causes of anaemia and associated cause-specific shifts in haemoglobin concentrations, we modelled the proportion of anaemia attributed to 37 underlying causes for all locations, years, and demographics in the Global Burden of Disease Study 2021. Findings In 2021, the global prevalence of anaemia across all ages was 24·3% (95% uncertainty interval [UI] 23·9–24·7), corresponding to 1·92 billion (1·89–1·95) prevalent cases, compared with a prevalence of 28·2% (27·8–28·5) and 1·50 billion (1·48–1·52) prevalent cases in 1990. Large variations were observed in anaemia burden by age, sex, and geography, with children younger than 5 years, women, and countries in sub-Saharan Africa and south Asia being particularly affected. Anaemia caused 52·0 million (35·1–75·1) YLDs in 2021, and the YLD rate due to anaemia declined with increasing Socio-demographic Index. The most common causes of anaemia YLDs in 2021 were dietary iron deficiency (cause-specific anaemia YLD rate per 100 000 population: 422·4 [95% UI 286·1–612·9]), haemoglobinopathies and haemolytic anaemias (89·0 [58·2–123·7]), and other neglected tropical diseases (36·3 [24·4–52·8]), collectively accounting for 84·7% (84·1–85·2) of anaemia YLDs. Interpretation Anaemia remains a substantial global health challenge, with persistent disparities according to age, sex, and geography. Estimates of cause-specific anaemia burden can be used to design locally relevant health interventions aimed at improving anaemia management and prevention. Funding Bill & Melinda Gates Foundation

En undersökning av samspelet mellan grafiska gränssnitt, huvudrörelser och dess inverkan för användarupplevelsen i virtuell verklighet

I denna rapport undersöks samspelet mellan grafiska gränssnitt, huvudrörelser och dess inverkan för användarupplevelsen i virtuell verklighet. Studien begränsas till applicering i fastighetsvisningsapplikationer i virtuell verklighet. Studien och rapportens syfte är att besvara frågeställningen: Vilka aspekter bör tas i åtanke vid utformningen av grafiska gränssnitt för huvudrörelsebaserade inmatningsmetoder till VR-mjukvara. Denna fråga kommer besvaras med designriktlinjer orienterade för virtuell verklighet. I bakgrunden presenteras definitioner och användning av termer som: Virtuell verklighet, grafiska gränssnitt, inmatningsmetoder och huvudrörelseinmatning. I bakgrunden presenteras även företagssamarbetet med Wec360 samt riktlinjer om grafiska gränssnitt i virtuell verklighet som ligger till grund för studiens innehåll. Därefter följer ett metodkapitel som presenterar, definierar samt förklarar användning av de test- och utvärderingsmetoder som används i kommande tester. Dessa tester och utvärderingar är en heuristisk utvärdering för att finna primära problemområden som ligger som bas för kommande användbarhetstest. Men innan dess utfördes en semistrukturerad intervju med fem(5) personer som är utan, eller har mindre erfarenhet av virtuell verklighet. Dessa intervjuer utfördes för att få en grundlig idé om preferens, attityd, beteende, användning, erfarenhet samt preliminära tankar. Med samma fem deltagare utfördes ett användbarhetstest vars primära syfte var att säkerställa eller dementera de problem som uppfattades under den heuristiska utvärderingen. Användbarhetstestet användes även för att upptäcka nya problemområden som ska analyseras. Därefter följde en analys som följde bottom up-metoden för att ta alla delade problem och föra samman till en helhetsbild som studiens resultat därefter baseras på. Därefter följer resultatet – tre riktlinjer med mål att förbättra aspekter för det grafiska gränssnittet och huvudrörelseinmatning med syfte att förbättra användarupplevelsen. De främsta resultaten visas gälla applikationens sämre synlighet av interaktiva grafiska element. Men även en inkräktande upplevelse bildad av grafiska förflyttningselement. Det slutliga resultatet berörde hjälpavsnitt och hur användaren visas var funktioner och element finns i applikationen samt hur de används. Slutligen följer slutsatser och tillhörande diskussion för vidare studier inom området för användarupplevelse och grafiska gränssnitt i virtuell verklighet